Pacritinib to Inhibit JAK/STAT Signaling in Refractory Colorectal Cancer

Part of paid clinical trials in St Louis, Missouri.

Sponsor
Washington University School of Medicine
Study ID
NCT02277093
Phase
PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The investigators propose to assess the efficacy, progression-free survival, and adverse events of pacritinib in patients with refractory colorectal cancer.

Key Dates

Start date
Sep 22, 2015
Status verified
Apr 2017
Primary completion
Mar 31, 2016
Completion
Oct 27, 2016

Study Design

Enrollment
11 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Pacritinib
    * Pacritinib is an oral drug which will be taken on an outpatient basis daily on a 28-day cycle at a dose of 200 mg twice a day (BID) * Pacritinib should be take at approximately the same times every day with a glass of water, with or without food

Primary Outcome Measure

Progression-free Survival (PFS) [ Time Frame: Through completion of follow-up (median follow-up was 6.61 months) ]

Locations (1)

FacilityCityStateZIPSite coordinators
Washington University School of MedicineSt LouisMissouri63110-

Find similar trials in St Louis, MO

By condition
Colorectal cancer
By specialty
OncologyGI oncology
By research site
Washington University School of Medicine· St Louis, MO

Related Studies